Therefore, clinical challenges remain to determine which tumor type(s) from which tissues of origin will be most likely to respond to Aurora B inhibitors and what other genetic or environmental factors contribute to the biological responses (e.g., cell cycle arrest in pseudo-G1, mitotic catastrophe, apoptosis, endoreduplication, cellular senescence, etc.)of tumor cells. Here, AURKB is linked to neoplasm.